Yellow Fever Vaccination of a Primary Vaccinee During Adalimumab Therapy

Authors

Esther R. Nash, Industrial Medical Center, Bridgeport Hospital, Bridgeport, CT, USA.
Myron Brand, Division of Internal Medicine, Yale University School of Medicine, New Haven, CT, USA.
Spyridon Chalkias, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.

Document Type

Article

Publication Title

Journal of travel medicine

Abstract

In this case report, we describe a 63-year-old female with Crohn's disease since age 16 years, and on adalimumab therapy, who inadvertently received a yellow fever vaccine (YFV) 4 days before her next dose of adalimumab. She had never received YFV. Her next dose of tumor necrosis factor (TNF) antagonist was held. She did not report any adverse effects referable to the vaccine. Reverse transcriptase-polymerase chain reaction (RT-PCR) for yellow fever (YF) viral RNA on days 12 and 18 postvaccination was negative. Neutralizing antibody to YF virus vaccine was immunoprotective on day 18 following vaccination, which further increased by day 26. A neutralizing antibody obtained 2 years following vaccination also remained immunoprotective.

First Page

279

Last Page

81

DOI

10.1111/jtm.12209

Publication Date

1-1-2015

Recommended Citation

Nash, Esther R.; Brand, Myron; and Chalkias, Spyridon, "Yellow Fever Vaccination of a Primary Vaccinee During Adalimumab Therapy" (2015). All Research. 293.
https://scholar.bridgeporthospital.org/all_research/293

Identifier

25922988 (pubmed); 10.1111/jtm.12209 (doi)